Sabitar 97 mg+103 mg (Tablet)
Unit Price: ৳ 120.00 (1 x 10: ৳ 1,200.00)
Strip Price: ৳ 1,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- Usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
Pharmacology
- Contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan.
- Inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan.
- Cardiovascular and renal effects attributed to increased levels of peptides degraded by neprilysin and simultaneous inhibition of the effects of angiotensin II by valsartan.
Dosage & Administration
- Recommended starting dose for adult heart failure is 49/51 mg orally twice daily.
- Recommended starting dose for pediatric heart failure varies based on weight.
- Dose titration guidelines for pediatric patients based on weight categories.
Interaction
- Should not be used with an ACE inhibitor, aliskiren in patients with diabetes, and use with an ARB should be avoided.
- Potassium-sparing diuretics may increase serum potassium levels.
- NSAIDs may increase the risk of renal impairment.
- Increased risk of lithium toxicity when used with lithium.
Contraindications
- Contraindicated in patients with hypersensitivity to any component.
- Contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy.
- Contraindicated with concomitant use of ACE inhibitors or aliskiren in patients with diabetes.
Side Effects
- Angioedema
- Hypotension
- Impaired Renal Function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age.
- No relevant pharmacokinetic differences observed in elderly patients.
- No dose adjustment required in patients with mild hepatic impairment.
- Not recommended in patients with severe hepatic impairment.
- No dose adjustment required in patients with mild to moderate renal impairment.
- Recommended starting dose in patients with severe renal impairment is 24/26 mg twice daily.
Precautions & Warnings
- May cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy.
- Lowers blood pressure and may cause symptomatic hypotension.
- Monitor serum potassium levels and treat appropriately in patients with risk factors for hyperkalemia.
- Dosage reduction or interruption may be required in certain conditions.
Use in Special Populations
- Safety and effectiveness not established in pediatric patients.
- No relevant pharmacokinetic differences observed in elderly patients.
- Dosage recommendations for patients with severe, mild, or moderate renal impairment.
- Dosage recommendations for patients with severe, moderate, or mild hepatic impairment.
Overdose Effects
- Limited data available regarding overdosage.
- Hypotension is the most likely result of overdosage.
- Symptomatic treatment should be provided.
- Unlikely to be removed by hemodialysis due to high protein binding.
Storage Conditions
- Keep in a dry place and store below 30°C.
- Protect from moisture and keep out of the reach of children.